Author: biocytogen

Syngeneic Mouse Models and Humanized Immune-Checkpoint Mice

June 17, 2020

Why do we need Syngeneic Mouse Models? To test potential immuno-oncology therapeutics in vivo, it is necessary to ensure that the disease model used has an intact immune system. Immunotherapeutics work with the body’s immune system to fight cancer cells. Often through inhibiting specific cell receptors called immune checkpoints, immunotherapeutics seek to bind to receptors […]

Read More

Online: Tumor Models Boston Summit 2020

June 17, 2020

Advancing Your Preclinical Models to Overcome Tumor Resistance, Effectively Target Solid Tumors & Increase Your Clinical Predictability Time: Saturday, July 15 2020. 9:30 AM EST. Register now! We continue to monitor the global impacts of COVID-19, and as the world adapts to the new way of living and scientific research, so do we. With a mission […]

Read More

Online Webinar: Humanized Animal Models for Immunotherapy

June 17, 2020

Biocytogen Informational Webinar Topic: Improve Translation of Humanized Animal Models for Immunotherapy Date: Thursday, July 16 2020, 11am-12pm EST. Webinar Description: Despite significant advances have been made in developing novel therapeutics for cancer treatment, only about five percent of new cancer drugs are approved, and most fail due to lack of translation from preclinical results […]

Read More

AACR Virtual Annual Meeting II (Poster Session)

June 3, 2020

The AACR Foundation is the philanthropic arm of the American Association for Cancer Research (AACR). The Foundation supports the groundbreaking work of the AACR and its more than 47,000 members on the front lines of the global effort to eradicate cancer. The AACR Annual Meeting program covers the latest discoveries across the spectrum of cancer […]

Read More

Biocytogen is Featured in GEN’s Immunotherapy and Cancer Supplement Issue

April 10, 2020

Developing animal models for immunotherapy is often difficult due to the complexity of the immune system and tumor biology. Showcased in April’s GEN Magazine, Biocytogen presents a line of target-humanized mice models, covering a growing portfolio of immune checkpoints and cytokines alongside its flagship RenMab fully human antibody mouse. Biocytogen has also developed the immunodeficient […]

Read More

Biocytogen CEO’s Response During COVID-19 Pandemic

April 8, 2020

Dear Valued Customer, The COVID-19 global outbreak has undoubtedly brought upon difficult times for individuals, families, and businesses around the world. Many of us have never experienced an interruption of life at this scale. Amid this turmoil, I wanted to provide some status updates. Today, I am very glad to let you know that all […]

Read More

Biocytogen Announces Dr. Zhaoxue (Luke) Yu as Global Head of Preclinical Pharmacology

April 2, 2020

On March 31st, Biocytogen announced Dr. Zhaoxue (Luke) Yu as our Global Head of Preclinical Pharmacology. As our global preclinical pharmacology team leader, Dr. Yu is dedicated to furthering Biocytogen’s innovative antibody discovery platform and serving as our liaison person for strategic partnerships between Biocytogen and external collaborators. Dr. Yu brings more than 15 years […]

Read More

April Webinar: In Vivo vs. In Vitro Therapeutic Antibody Discovery

March 23, 2020

Date: April 16th, 2020 | 11am EST Presenter: Lei Chen,  Ph.D. Senior Director of Antibody Discovery of Biocytogen REGISTER NOW About the webinar in vivo antibody discovery using transgenic/humanized mice is of rising importance for the antibody community as it offers a multitude of benefits over in vitro methods (such as phage display of immune libraries) and humanization […]

Read More

Gene Targeting Service Verified with Industry-leading Quality Control Measures

March 12, 2020

  At Biocytogen, we take pride in our quality control measures when we target and edit genes for our mouse models and drug development endeavors. From preventing potentially disastrous results before they occur to instituting reliable, tried-and-true protocols, proper attention to quality control when gene-editing can save clients both time and resources. For example, based […]

Read More

GEN Magazine Mentions Biocytogen and Its Humanized Mice Model

March 6, 2020

Showcased in GEN Magazine’s March issue, Biocytogen speaks about the current state and imminent future of animal models, specifically on the humanization of mouse models for complex drug development challenges. Senior vice president of Biocytogen and CEO of Biocytogen Boston Qingcong Lin, PhD is featured alongside executives at Charles River Laboratories, Taconic Biosciences, Jackson Laboratory, […]

Read More

Back to top